Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Aspirin for primary stroke prevention in elderly patients with vascular risk factors.

Uchiyama S.

J Gen Fam Med. 2017 Jun 21;18(6):331-335. doi: 10.1002/jgf2.102. eCollection 2017 Dec. Review.

2.

Reduced Dietary Selenium Impairs Vascular Function by Increasing Oxidative Stress in Sprague-Dawley Rat Aortas.

Stupin A, Cosic A, Novak S, Vesel M, Jukic I, Popovic B, Karalic K, Loncaric Z, Drenjancevic I.

Int J Environ Res Public Health. 2017 Jun 2;14(6). pii: E591. doi: 10.3390/ijerph14060591.

3.

Platelets, diabetes and myocardial ischemia/reperfusion injury.

Russo I, Penna C, Musso T, Popara J, Alloatti G, Cavalot F, Pagliaro P.

Cardiovasc Diabetol. 2017 May 31;16(1):71. doi: 10.1186/s12933-017-0550-6. Review.

4.

Dietary Supplements and Risk of Cause-Specific Death, Cardiovascular Disease, and Cancer: A Systematic Review and Meta-Analysis of Primary Prevention Trials.

Schwingshackl L, Boeing H, Stelmach-Mardas M, Gottschald M, Dietrich S, Hoffmann G, Chaimani A.

Adv Nutr. 2017 Jan 17;8(1):27-39. doi: 10.3945/an.116.013516. Print 2017 Jan. Review.

5.

The Benefit and Safety of Aspirin for Primary Prevention of Ischemic Stroke: A Meta-Analysis of Randomized Trials.

Lei H, Gao Q, Liu SR, Xu J.

Front Pharmacol. 2016 Nov 18;7:440. eCollection 2016. Review.

6.

Lower Platelet Reactivity Is Associated with Presentation of Unstable Coronary Artery Disease.

Leunissen TC, Gijsberts CM, Wisman PP, Huisman A, Berg MT, Asselbergs FW, Hoefer IE, Pasterkamp G, Moll FL, de Borst GJ, Roest M.

Int J Angiol. 2016 Dec;25(4):210-218. Epub 2016 Oct 24.

7.

Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk.

Elwood PC, Morgan G, Galante J, Chia JW, Dolwani S, Graziano JM, Kelson M, Lanas A, Longley M, Phillips CJ, Pickering J, Roberts SE, Soon SS, Steward W, Morris D, Weightman AL.

PLoS One. 2016 Nov 15;11(11):e0166166. doi: 10.1371/journal.pone.0166166. eCollection 2016.

8.

Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies.

García Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A.

PLoS One. 2016 Aug 4;11(8):e0160046. doi: 10.1371/journal.pone.0160046. eCollection 2016. Review.

9.

Oxidative Stress Genes, Antioxidants and Coronary Artery Disease in Type 2 Diabetes Mellitus.

Tibaut M, Petrovič D.

Cardiovasc Hematol Agents Med Chem. 2016;14(1):23-38. Review.

10.

Aspirin for primary prevention of cardiovascular disease.

Nansseu JR, Noubiap JJ.

Thromb J. 2015 Dec 4;13:38. doi: 10.1186/s12959-015-0068-7. eCollection 2015. Review.

11.

Which people should take aspirin for primary prevention of cardiovascular disease?

Lozano R, Franco ME.

Ther Clin Risk Manag. 2015 Jul 2;11:1043-5. doi: 10.2147/TCRM.S88091. eCollection 2015. No abstract available.

12.

Investigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug Users.

Sogabe M, Okahisa T, Nakasono M, Fujino Y, Mitsui Y, Takaoka Y, Kimura T, Okamoto K, Muguruma N, Takayama T.

Medicine (Baltimore). 2015 Jul;94(26):e1047. doi: 10.1097/MD.0000000000001047.

13.

High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study.

Shlomai G, Haran-Appel T, Sella T, Grossman Y, Hauschner H, Rosenberg N, Grossman E.

Cardiovasc Diabetol. 2015 Jun 12;14:80. doi: 10.1186/s12933-015-0244-x.

14.

Antiplatelet therapy as a modulator of stroke aetiology: a meta-analysis.

Rajkumar CA, Floyd CN, Ferro A.

Br J Clin Pharmacol. 2015 Sep;80(3):331-41. doi: 10.1111/bcp.12630. Epub 2015 Jul 2.

15.

Dietary compliance, dietary supplementation and traditional remedy usage of type 2 diabetic patients with and without cardiovascular disease.

Tan MC, Ng OC, Wong TW, Joseph A, Hejar AR, Rushdan AA.

Clin Nutr Res. 2015 Jan;4(1):18-31. doi: 10.7762/cnr.2015.4.1.18. Epub 2014 Dec 22.

16.

A systematic review of aspirin in primary prevention: is it time for a new approach?

Brotons C, Benamouzig R, Filipiak KJ, Limmroth V, Borghi C.

Am J Cardiovasc Drugs. 2015 Apr;15(2):113-33. doi: 10.1007/s40256-014-0100-5. Review.

17.

Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.

Xie M, Shan Z, Zhang Y, Chen S, Yang W, Bao W, Rong Y, Yu X, Hu FB, Liu L.

PLoS One. 2014 Oct 31;9(10):e90286. doi: 10.1371/journal.pone.0090286. eCollection 2014.

18.

Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks?

Sirois C, Couture J, Grégoire JP.

Ther Adv Drug Saf. 2012 Oct;3(5):213-26. doi: 10.1177/2042098612451267. Review.

19.

A short-term effect of low-dose aspirin on major hemorrhagic risks in primary prevention: a case-crossover design.

Wu IC, Lin MY, Yu FJ, Hsieh HM, Chiu KF, Wu MT.

PLoS One. 2014 May 30;9(5):e98326. doi: 10.1371/journal.pone.0098326. eCollection 2014.

20.

Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis.

Miedema MD, Duprez DA, Misialek JR, Blaha MJ, Nasir K, Silverman MG, Blankstein R, Budoff MJ, Greenland P, Folsom AR.

Circ Cardiovasc Qual Outcomes. 2014 May;7(3):453-60. doi: 10.1161/CIRCOUTCOMES.113.000690. Epub 2014 May 6.

Supplemental Content

Support Center